TECregen

Executive Summary

TECregen is a Swiss biotechnology company pioneering a new class of regenerative biologics called 'thymopoietics,' designed to restore immune function by targeting thymus regeneration. Founded in 2018 and based in Geneva, the company leverages advanced ligand engineering and targeted delivery to create tissue-selective therapeutics. Their platform addresses critical unmet needs in immune decline, cancer, and inflammatory diseases, aiming to rebuild immune competence where current therapies fall short. By focusing on the thymus—the primary organ for T-cell development—TECregen's approach offers a novel mechanism to rejuvenate the aging immune system and improve outcomes in immuno-oncology and autoimmune conditions. The company is currently in the preclinical stage, advancing its lead thymopoietic candidates toward clinical development. With a strong intellectual property portfolio and a clear vision for first-in-class therapies, TECregen is positioned to disrupt the immunology and regenerative medicine landscape. The upcoming milestones, including financing and early clinical data, will be critical to validate its platform and attract strategic partnerships. If successful, TECregen could redefine treatment paradigms for immune-related diseases, addressing a large and growing market driven by an aging population and rising cancer incidence.

Upcoming Catalysts (preview)

• Q3 2026Series B financing to support IND-enabling studies60% success
• Q2 2027Initiation of first-in-human Phase 1 trial for lead thymopoietic candidate50% success
• Q4 2026Partnership with a top-tier pharma for thymus regeneration programs40% success